Evidence map›Paper›PMID 34982269›Full record

ArticleMedical oncology (Northwood, London, England)2022

IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme.

Dilara Akcora-Yildiz, Yunus Yukselten, Merve Sunguroglu, Hasan Caglar Ugur, Asuman Sunguroglu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  4. Article
  5. Article
  6. Frontiers in microbiology · 2025
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Dilara Akcora-YildizDepartment of Biology, Science & Art Faculty, Mehmet Akif Ersoy University, Burdur, Turkey.
Yunus YukseltenDepartment of Medical Biology, School of Medicine, Ankara University, Ankara, Turkey.
Merve SungurogluDepartment of Medical Biology, School of Medicine, Hacettepe University, Ankara, Turkey.
Hasan Caglar UgurDepartment of Neurosurgery, School of Medicine, Ankara University, Ankara, Turkey.
Asuman SungurogluDepartment of Medical Biology, School of Medicine, Ankara University, Ankara, Turkey. asungur@medicine.ankara.edu.tr.ORCID http://orcid.org/0000-0001-7693-0958
Ankara University · TRBurdur Mehmet Akif Ersoy Üniversitesi · TRHacettepe University · TRMinistry of Health · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM), characterized by a high rate of proliferation and migration capacity, is an incurable brain tumor in adults. Interleukin-33 (IL-33), a member of the IL-1 cytokine superfamily, and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), a family of zinc dependent metalloproteinases, are known to have essential roles in GBM migration and invasion. Previous studies have separately revealed elevated expressions of IL-33 and ADAMTS5 in GBM; however, the interaction between IL-33 and ADAMTS5 in GBM remains unclear. Here, using publically available GlioVis and GEPIA programs, we showed that mRNA expressions of IL-33 and ADAMTS5 are significantly high in GBM cells, and a positive correlation between IL-33 and ADAMTS5 was also determined in these cells. In parallel with the mRNA data of IL-33 and ADAMTS5, by Western blot analysis, protein levels were found to be elevated in GBM tissues and increased gradually with the disease progression. Primary GBM cells and low-grade glioma cells were then treated with IL-33 to examine its stimulating effect on ADAMTS5 expression. Exposure to IL-33 raised ADAMTS5 protein levels in a dose-dependent manner. Finally, the wound-healing method was performed to confirm the impact of IL-33 on migration in primary GBM cells. IL-33 promoted migration of primary GBM cells three times higher than untreated GBM cells. Thus, the current study suggests for the first time that IL-33 might have a role in playing a part in GBM progression through induction of ADAMTS5 expression and promotion of migration in GBM cells.

Indexed as

Gene Expression Regulation, NeoplasticADAMTS5 ProteinBrain NeoplasmsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGlioblastomaHumansInterleukin-33MaleMiddle AgedNeoplasm InvasivenessRNA, MessengerWound HealingADAMTS5 ProteinADAMTS5 protein, humanIL33 protein, humanInterleukin-33RNA, MessengerADAMTS5Glioblastoma multiformeIL-33Migration

Identifiers

PMID34982269
OpenAlexW4206591504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.